Attached article starts:
"Clinuvel to evaluate SCENESSE® as therapy in vitiligo
Pilot study to evaluate drug in pigmentary disorder affecting more than 45 million globally
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it will begin a pilot trial (CUV031) with its first-in-class drug SCENESSE® (afamelanotide) as a repigmentation therapy in the pigmentary disorder vitiligo. The trial will focus on patients diagnosed with nonsegmental vitiligo (NSV), the most common form of the disorder which affects approximately 45 million people globally.
"During an investigators’ meeting on 21 August in New York, Clinuvel reached agreement with four of the world’s most prominent and expert centres specialising in vitiligo. Consensus was reached on the protocol and study design. The trial is scheduled to start in October, subject to obtaining the necessary European and US regulatory approvals."
Read announcement in full attached.
Replies